Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 7/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1177473 | 1.00 | SLC6A4 (0.50) | SLC6A4SLC6A2CHRM1SLC6A3DRD3 | |
| Fumaric Acid SCHEMBL1177768 | 0.88 | SLC6A4 (0.41) | SLC6A4SLC6A2CHRM1SLC6A3 | |
| SCHEMBL7940536 | 0.82 | SLC6A3 (0.50) | SLC6A4SLC6A2CHRM1SLC6A3DRD3 | |
| SCHEMBL14573376 | 0.81 | CHRM1 (0.38) | SLC6A4SLC6A2CHRM1SLC6A3DRD3 | |
| SCHEMBL5634867 | 0.80 | OPRM1 (0.43) | SLC6A4SLC6A2CHRM1SLC6A3DRD3 | |
| SCHEMBL5636174 | 0.76 | L3MBTL1 (0.38) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL14573374 | 0.76 | L3MBTL1 (0.38) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL7940689 | 0.76 | CHRM1 (0.50) | SLC6A4SLC6A2CHRM1SLC6A3DRD3 | |
| SCHEMBL5636304 | 0.76 | SLC6A2 (0.40) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL5636307 | 0.76 | SLC6A2 (0.40) | SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888358-B2 | Serotonine, dopamine and norendrenaline receptors; antidepressants, anxiolytic agents, eating disorders; obesity; bipolar; drug abuse; neurodegenerative diseases | NEUROSEARCH A/S (DK) | 2011-02-15 | — | — | US | claimed |
| US-20080269229-A1 | Novel 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | PETERS DAN | 2008-10-30 | — | — | US | claimed |
| US-20060142331-A1 | Novel 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | DANPET AB (SE) | 2006-06-29 | — | — | US | claimed |
| EP-1638965-A1 | NOVEL 8-AZA-BICYCLO¬3.2.1|OCTANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2006-03-29 | — | — | EP | claimed |
| WO-2004113334-A1 | NOVEL 8-AZA-BICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2004-12-29 | — | — | WO | claimed |
| US-20110112139-A1 | NOVEL 8-AZA-BICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | PETERS DAN | 2011-05-12 | — | — | US | disclosed |
| US-7888358-B2 | Serotonine, dopamine and norendrenaline receptors; antidepressants, anxiolytic agents, eating disorders; obesity; bipolar; drug abuse; neurodegenerative diseases | NEUROSEARCH A/S (DK) | 2011-02-15 | — | — | US | disclosed |
| US-20080269229-A1 | Novel 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | PETERS DAN | 2008-10-30 | — | — | US | disclosed |
| US-7407970-B2 | 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2008-08-05 | — | — | US | disclosed |
| US-20060142331-A1 | Novel 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | DANPET AB (SE) | 2006-06-29 | — | — | US | disclosed |
| EP-1638965-A1 | NOVEL 8-AZA-BICYCLO¬3.2.1|OCTANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2006-03-29 | — | — | EP | disclosed |
| WO-2004113334-A1 | NOVEL 8-AZA-BICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269229-A1 | Novel 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | SLC18A2, SLC18A3, SLC6A2 | SLC6A4 7/4885SLC6A2 3/4885CHRM1 213/4885 |
| US-20060142331-A1 | Novel 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | SLC18A2, SLC18A3, SLC6A2 | SLC6A4 7/4885SLC6A2 3/4885CHRM1 213/4885 |
| US-20110112139-A1 | NOVEL 8-AZA-BICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC18A3, SLC6A2 | SLC6A4 7/4885SLC6A2 3/4885CHRM1 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.